The meta-analysis, published today in The Lancet Oncology, by Sipahi and colleagues1 is disturbing and provocative, raising crucial drug safety questions for practitioners and the regulatory community. Are angiotensin-receptor blockers (ARBs) associated with increased risk of incident malignancies? Should we be concerned about all ARBs or a single drug, telmisartan? How can this uncertainty best be resolved? What actions should practitioners take while this concern undergoes further examination and analysis?

source: Lancet oncology